BeyondSpring (NASDAQ:BYSI – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.52, FiscalAI reports.
BeyondSpring Price Performance
Shares of NASDAQ:BYSI traded down $0.16 during trading on Friday, reaching $0.84. 777,182 shares of the company’s stock traded hands, compared to its average volume of 282,435. The stock has a market capitalization of $34.50 million, a P/E ratio of -5.99 and a beta of 0.48. BeyondSpring has a 12 month low of $0.73 and a 12 month high of $2.44. The company has a 50 day moving average of $1.39 and a 200-day moving average of $1.50.
Hedge Funds Weigh In On BeyondSpring
An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC increased its stake in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the period. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 40.29% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on BeyondSpring
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
See Also
- Five stocks we like better than BeyondSpring
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
